Sonic says COVID-19 vaccine will create a surge in missed routine testing

Carrie LaFrenzSenior reporter

Updated Feb 18, 2021 – 10.38am, first published at 8.45am

Email LinkedIn Twitter Facebook

Subscribe to gift this article

Gift 5 articles to anyone you choose each month when you subscribe.

Subscribe now

Already a subscriber?

Key Points

Revenue ($m): 4432 v year-earlier 3341
Pre-tax profit ($m): 944 v 347.4
Net profit ($m): 678 v 254
Dividend: 36c, payable March 24

Vaccination programs around the world will create a surge in routine testing that has been missed amid pandemic fears of going to the doctor, says Sonic Healthcare boss Colin Goldschmidt.

In Australia, there has been a rebound in anatomical pathology testing at the nation’s largest private pathology player for items such as pap smear tests, used to detect cervical cancer, which have been skipped.

Carrie LaFrenz is a senior journalist covering retail/consumer goods. She previously covered healthcare/biotech. Carrie has won multiple awards for her journalism including financial journalist of the year from The National Press Club.